Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
July 22, 2024 7:00 AM EDT
ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect input from parents and clinicians97% of patients in the medium and high dose groups saw improvement in overall Angelman syndrome symptoms as measured by the SAS-CGI-C Improvements on the Bayley-4 in cognition, communication and motor function exceeded those observed in natural history studiesIonis plans to initiate Phase 3 development in H1 2025Ionis to host webcast on Monday, July 22 at... More
July 19, 2024 8:24 AM EDT
Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time
CARLSBAD, Calif., July 19, 2024 /PRNewswire/... More
July 18, 2024 7:00 AM EDT
Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition
CARLSBAD, Calif., July 18, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS)Â announced today that it has completed enrollment in the pivotal trial of zilganersen... More
